Pfizer
Headquarters country
United States
Registry sponsor category
Industry
- Company name
- Pfizer
- Organisation type
- Industry
- Registered legal name
- PFIZER INC.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Pfizer Inc. (Provider of study drugs)
- Pfizer
- SEC filer number (CIK)
- 0000078003
- Legal Entity Identifier (LEI)
- 765LHXWGK1KXCLTFYQ30
Related records
Subsidiaries (3)
- Parke-Davis Indirect subsidiary
- Pharmacia Indirect subsidiary
- Pharmacia and Upjohn Direct subsidiary
Trials (4,880)
- "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
- "VIBRATIONS" - A Study In Smokers Who Are Willing And Motivated To Stop Smoking With The Aid Of Varenicline Which Will Be Prescribed According To Usual Clinical Practice In Germany
- [S,S]-Reboxetine Add-On Trial
- [S,S]-Reboxetine Dose-Range Finding Trial
- [S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.
- [S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.
- 12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
- 12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
- 12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
- 12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin
- 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
- 13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients
- 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
- 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
- 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
- 2-Week Study In People With Nonalcoholic Fatty Liver Disease
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants